Back to Search
Start Over
Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer
- Source :
- Journal of Cellular Physiology. 233:2058-2066
- Publication Year :
- 2017
- Publisher :
- Wiley, 2017.
-
Abstract
- The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently dysregulated in colorectal cancer (CRC). It is involved in the modulation of several downstream effectors, that include: Raf/Mek/Erk, PI3K/Akt, RalGDS/p38MAPK, and Rac/Rho, and thereby influences tumorigenesis, the invasive behaviors of tumor cell, and resistance to therapy. There is growing evidence exploring the use of drugs that target these pathways in the treatment of CRC. Cetuximab has been approved for CRC patients without a KRAS mutation, or for EGFR-expressing metastatic CRC, although some of the patients have a mutation of KRAS and NRAS. This review summarizes the recent knowledge about the therapeutic potential of targeting RAS with particular emphasis on recent preclinical and clinical studies in treatment of CRC.
- Subjects :
- 0301 basic medicine
Neuroblastoma RAS viral oncogene homolog
MAPK/ERK pathway
Pyridines
Physiology
Colorectal cancer
Clinical Biochemistry
Cetuximab
medicine.disease_cause
GTP Phosphohydrolases
Proto-Oncogene Proteins p21(ras)
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
medicine
Humans
neoplasms
PI3K/AKT/mTOR pathway
business.industry
Panitumumab
Phenylurea Compounds
Antibodies, Monoclonal
Membrane Proteins
Cell Biology
medicine.disease
digestive system diseases
ErbB Receptors
Cell Transformation, Neoplastic
030104 developmental biology
Ras Signaling Pathway
030220 oncology & carcinogenesis
Immunology
Cancer research
KRAS
Colorectal Neoplasms
Carcinogenesis
business
medicine.drug
Subjects
Details
- ISSN :
- 00219541
- Volume :
- 233
- Database :
- OpenAIRE
- Journal :
- Journal of Cellular Physiology
- Accession number :
- edsair.doi.dedup.....08646eac716e00b0d15fc6ce68ad42c3